Global Key SolutionsGKS
Guidance Documents/Guidance-Document/Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products

Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products

Detailed guidance document from FDA and regulatory agencies.

Document Details

Guidance Document

February 1, 2023

January 31, 2023

Center for Drug Evaluation and Research

9dafe0c9-19d4-48c0-a1ca-6b2a04a813ed

Related Documents

Meta-Analyses of Randomized Controlled Clinical Trials to Evaluate the Safety of Human Drugs or Biological Products

Guidance DocumentNovember 7, 2018Center for Drug Evaluation and Research
View Details →

Integrating Randomized Controlled Trials for Drug and Biological Products Into Routine Clinical Practice: Draft Guidance for Industry

Guidance DocumentSeptember 18, 2024Center for Drug Evaluation and Research
View Details →

Real-World Evidence: Considerations Regarding Non-Interventional Studies for Drug and Biological Products

Guidance DocumentMarch 21, 2024Center for Drug Evaluation and Research
View Details →

Quick Actions

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Transform Regulatory Data into Actionable Intelligence

Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.

Try KeyPedia Today

Explore our real use cases and discover our features in depth.

Subscribe to our newsletter

Get the latest updates and insights delivered to your inbox

footer
Global Key Solutions
Regulatory Data Transformed
Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
[email protected]
Quick Links
KeyPedia™ Lite
Legal & Ethics
©2026, Global Key Solutions All rights reserved.